FINANCINGS
Armetheon Inc. closed a $24.3 million series B financing round.
Ascendis Pharma A/S closed its IPO with estimated net proceeds of about $111.5 million.
Aurasense Therapeutics LLC completed a second closing of a series C financing, propelling the round to more than $18 million.
Bind Therapeutics Inc. priced a public offering for gross proceeds of about $21.5 million.
Brickell Biotech Inc. disclosed a $10 million series C financing round.
Catalyst Pharmaceutical Partners Inc. priced its public offering of 10 million shares at $3.25 per share.
Epirus Biopharmaceuticals Inc. priced a public offering for net proceeds of about $44.2 million.
Flex Pharma Inc. closed its IPO of 5.4 million shares of common stock at $16 each for gross proceeds of $86.4 million.
G1 Therapeutics Inc. raised $33 million from a series B financing round.
Intercept Pharmaceuticals Inc. priced a public offering of 1 million shares at $176 each.
Lysosomal Therapeutics Inc. raised $20 million in series A financing.
Mirati Therapeutics Inc. closed its public offering for gross proceeds of approximately $51.8 million.
Omeros Corp. closed its public offering for gross proceeds of approximately $84 million.
Orbimed closed a second health care royalty fund, Orbimed Royalty Opportunities II LP, with $924 million in commitments.
Quantum Genomics SA is seeking about $10 million in a discounted share issue on the Alternext market in Paris.
Spark Therapeutics Inc. completed an upsized IPO raising $161 million.
Summit Corp. plc has filed an F-1 with the SEC seeking to raise $40 million in an IPO.
Xbiotech Inc. filed for an IPO.
Ziopharm Oncology Inc. priced a public offering of 10 million shares at $8.75 each.
DEALS
Astrazeneca plc is acquiring the rights to Actavis plc's branded respiratory business in the U.S. and Canada.
Immunomic Therapeutics Inc. inked an agreement with Astellas Pharma Inc. to develop and commercialize its JRC2-LAMP-vax to treat allergies induced by Japanese red cedar pollen, in Japan.
Matinas Biopharma Holdings Inc. acquired Aquarius Biotechnologies Inc., a bio-delivery drug discovery company.
Moderna Therapeutics Inc. and the Institut Pasteur are collaborating to develop drugs and vaccines using Moderna's messenger RNA therapeutics platform.
Pfizer Inc. is acquiring Hospira Inc. for $90 per share in cash in a deal valued at approximately $17 billion.
Rxi Pharmaceuticals Corp. closed its license agreement for the use of Samcyprone with Hapten Pharmaceuticals LLC.
The Medicines Co. completed its acquisition of Annovation Biopharma Inc., a company focused on creating therapies for anesthesia and critical care.
. . . AND MORE
A Nuffield Council on Bioethics report examines the significant ethical questions posed by the rise of big data and rapid advances in the acquisition, linking, analysis, use and exploitation of biological and health care information.
Pfizer Inc.'s cyclin-dependent kinase inhibitor palbociclib won FDA approval for use in metastatic breast cancer.
Stemline Therapeutics Inc. gained an FDA orphan designation for the use of SL-701 in treating gliomas.
Tengion Inc. started a bankruptcy proceeding filing for a voluntary chapter 7 bankruptcy protection.
The UK has become the first country in the world to approve the use of mitochondria donation to prevent inherited mitochondrial diseases, with members of parliament voting in favor in a free vote last week.